The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Hospital Acquired Pneumonia Drugs Market Research Report 2024
Synopsis
Hospital-acquired pneumonia (HAP) or nosocomial pneumonia refers to any pneumonia contracted by a patient in a hospital at least 48–72 hours after being admitted. It is thus distinguished from community-acquired pneumonia. It is usually caused by a bacterial infection, rather than a virus.
The global Hospital Acquired Pneumonia Drugs market was valued at US$ 2807.5 million in 2023 and is anticipated to reach US$ 3218.1 million by 2030, witnessing a CAGR of 1.5% during the forecast period 2024-2030.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report aims to provide a comprehensive presentation of the global market for Hospital Acquired Pneumonia Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hospital Acquired Pneumonia Drugs.
Report Scope
The Hospital Acquired Pneumonia Drugs market size, estimations, and forecasts are provided in terms of sales volume (Kg) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hospital Acquired Pneumonia Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hospital Acquired Pneumonia Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Basilea Pharmaceutica
Meiji Holdings
Cubist Pharmaceutical
Aridis Pharmaceutical
Valneva
Bayer
GlaxoSmithKline
Merck
Achaogen
AstraZeneca
Segment by Type
Phase II
Early Phase (Phase I & II)
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Drug Store
E-Commerce
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Hospital Acquired Pneumonia Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Hospital Acquired Pneumonia Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Hospital-acquired pneumonia (HAP) or nosocomial pneumonia refers to any pneumonia contracted by a patient in a hospital at least 48–72 hours after being admitted. It is thus distinguished from community-acquired pneumonia. It is usually caused by a bacterial infection, rather than a virus.
The global Hospital Acquired Pneumonia Drugs market was valued at US$ 2807.5 million in 2023 and is anticipated to reach US$ 3218.1 million by 2030, witnessing a CAGR of 1.5% during the forecast period 2024-2030.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report aims to provide a comprehensive presentation of the global market for Hospital Acquired Pneumonia Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hospital Acquired Pneumonia Drugs.
Report Scope
The Hospital Acquired Pneumonia Drugs market size, estimations, and forecasts are provided in terms of sales volume (Kg) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hospital Acquired Pneumonia Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hospital Acquired Pneumonia Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Basilea Pharmaceutica
Meiji Holdings
Cubist Pharmaceutical
Aridis Pharmaceutical
Valneva
Bayer
GlaxoSmithKline
Merck
Achaogen
AstraZeneca
Segment by Type
Phase II
Early Phase (Phase I & II)
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Drug Store
E-Commerce
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Hospital Acquired Pneumonia Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Hospital Acquired Pneumonia Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Hospital Acquired Pneumonia Drugs Market Overview
1.1 Product Overview and Scope of Hospital Acquired Pneumonia Drugs
1.2 Hospital Acquired Pneumonia Drugs Segment by Type
1.2.1 Global Hospital Acquired Pneumonia Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Phase II
1.2.3 Early Phase (Phase I & II)
1.3 Hospital Acquired Pneumonia Drugs Segment by Application
1.3.1 Global Hospital Acquired Pneumonia Drugs Market Value by Application: (2024-2030)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Drug Store
1.3.5 E-Commerce
1.4 Global Hospital Acquired Pneumonia Drugs Market Size Estimates and Forecasts
1.4.1 Global Hospital Acquired Pneumonia Drugs Revenue 2019-2030
1.4.2 Global Hospital Acquired Pneumonia Drugs Sales 2019-2030
1.4.3 Global Hospital Acquired Pneumonia Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Hospital Acquired Pneumonia Drugs Market Competition by Manufacturers
2.1 Global Hospital Acquired Pneumonia Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Hospital Acquired Pneumonia Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Hospital Acquired Pneumonia Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Hospital Acquired Pneumonia Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Hospital Acquired Pneumonia Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Hospital Acquired Pneumonia Drugs, Product Type & Application
2.7 Hospital Acquired Pneumonia Drugs Market Competitive Situation and Trends
2.7.1 Hospital Acquired Pneumonia Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Hospital Acquired Pneumonia Drugs Players Market Share by Revenue
2.7.3 Global Hospital Acquired Pneumonia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Hospital Acquired Pneumonia Drugs Retrospective Market Scenario by Region
3.1 Global Hospital Acquired Pneumonia Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Hospital Acquired Pneumonia Drugs Global Hospital Acquired Pneumonia Drugs Sales by Region: 2019-2030
3.2.1 Global Hospital Acquired Pneumonia Drugs Sales by Region: 2019-2024
3.2.2 Global Hospital Acquired Pneumonia Drugs Sales by Region: 2025-2030
3.3 Global Hospital Acquired Pneumonia Drugs Global Hospital Acquired Pneumonia Drugs Revenue by Region: 2019-2030
3.3.1 Global Hospital Acquired Pneumonia Drugs Revenue by Region: 2019-2024
3.3.2 Global Hospital Acquired Pneumonia Drugs Revenue by Region: 2025-2030
3.4 North America Hospital Acquired Pneumonia Drugs Market Facts & Figures by Country
3.4.1 North America Hospital Acquired Pneumonia Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Hospital Acquired Pneumonia Drugs Sales by Country (2019-2030)
3.4.3 North America Hospital Acquired Pneumonia Drugs Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Hospital Acquired Pneumonia Drugs Market Facts & Figures by Country
3.5.1 Europe Hospital Acquired Pneumonia Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Hospital Acquired Pneumonia Drugs Sales by Country (2019-2030)
3.5.3 Europe Hospital Acquired Pneumonia Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Hospital Acquired Pneumonia Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Hospital Acquired Pneumonia Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Hospital Acquired Pneumonia Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Hospital Acquired Pneumonia Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Hospital Acquired Pneumonia Drugs Market Facts & Figures by Country
3.7.1 Latin America Hospital Acquired Pneumonia Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Hospital Acquired Pneumonia Drugs Sales by Country (2019-2030)
3.7.3 Latin America Hospital Acquired Pneumonia Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Hospital Acquired Pneumonia Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Hospital Acquired Pneumonia Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Hospital Acquired Pneumonia Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Hospital Acquired Pneumonia Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Hospital Acquired Pneumonia Drugs Sales by Type (2019-2030)
4.1.1 Global Hospital Acquired Pneumonia Drugs Sales by Type (2019-2024)
4.1.2 Global Hospital Acquired Pneumonia Drugs Sales by Type (2025-2030)
4.1.3 Global Hospital Acquired Pneumonia Drugs Sales Market Share by Type (2019-2030)
4.2 Global Hospital Acquired Pneumonia Drugs Revenue by Type (2019-2030)
4.2.1 Global Hospital Acquired Pneumonia Drugs Revenue by Type (2019-2024)
4.2.2 Global Hospital Acquired Pneumonia Drugs Revenue by Type (2025-2030)
4.2.3 Global Hospital Acquired Pneumonia Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Hospital Acquired Pneumonia Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Hospital Acquired Pneumonia Drugs Sales by Application (2019-2030)
5.1.1 Global Hospital Acquired Pneumonia Drugs Sales by Application (2019-2024)
5.1.2 Global Hospital Acquired Pneumonia Drugs Sales by Application (2025-2030)
5.1.3 Global Hospital Acquired Pneumonia Drugs Sales Market Share by Application (2019-2030)
5.2 Global Hospital Acquired Pneumonia Drugs Revenue by Application (2019-2030)
5.2.1 Global Hospital Acquired Pneumonia Drugs Revenue by Application (2019-2024)
5.2.2 Global Hospital Acquired Pneumonia Drugs Revenue by Application (2025-2030)
5.2.3 Global Hospital Acquired Pneumonia Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Hospital Acquired Pneumonia Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Basilea Pharmaceutica
6.1.1 Basilea Pharmaceutica Corporation Information
6.1.2 Basilea Pharmaceutica Description and Business Overview
6.1.3 Basilea Pharmaceutica Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Basilea Pharmaceutica Hospital Acquired Pneumonia Drugs Product Portfolio
6.1.5 Basilea Pharmaceutica Recent Developments/Updates
6.2 Meiji Holdings
6.2.1 Meiji Holdings Corporation Information
6.2.2 Meiji Holdings Description and Business Overview
6.2.3 Meiji Holdings Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Meiji Holdings Hospital Acquired Pneumonia Drugs Product Portfolio
6.2.5 Meiji Holdings Recent Developments/Updates
6.3 Cubist Pharmaceutical
6.3.1 Cubist Pharmaceutical Corporation Information
6.3.2 Cubist Pharmaceutical Description and Business Overview
6.3.3 Cubist Pharmaceutical Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Cubist Pharmaceutical Hospital Acquired Pneumonia Drugs Product Portfolio
6.3.5 Cubist Pharmaceutical Recent Developments/Updates
6.4 Aridis Pharmaceutical
6.4.1 Aridis Pharmaceutical Corporation Information
6.4.2 Aridis Pharmaceutical Description and Business Overview
6.4.3 Aridis Pharmaceutical Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Aridis Pharmaceutical Hospital Acquired Pneumonia Drugs Product Portfolio
6.4.5 Aridis Pharmaceutical Recent Developments/Updates
6.5 Valneva
6.5.1 Valneva Corporation Information
6.5.2 Valneva Description and Business Overview
6.5.3 Valneva Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Valneva Hospital Acquired Pneumonia Drugs Product Portfolio
6.5.5 Valneva Recent Developments/Updates
6.6 Bayer
6.6.1 Bayer Corporation Information
6.6.2 Bayer Description and Business Overview
6.6.3 Bayer Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Bayer Hospital Acquired Pneumonia Drugs Product Portfolio
6.6.5 Bayer Recent Developments/Updates
6.7 GlaxoSmithKline
6.6.1 GlaxoSmithKline Corporation Information
6.6.2 GlaxoSmithKline Description and Business Overview
6.6.3 GlaxoSmithKline Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 GlaxoSmithKline Hospital Acquired Pneumonia Drugs Product Portfolio
6.7.5 GlaxoSmithKline Recent Developments/Updates
6.8 Merck
6.8.1 Merck Corporation Information
6.8.2 Merck Description and Business Overview
6.8.3 Merck Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Merck Hospital Acquired Pneumonia Drugs Product Portfolio
6.8.5 Merck Recent Developments/Updates
6.9 Achaogen
6.9.1 Achaogen Corporation Information
6.9.2 Achaogen Description and Business Overview
6.9.3 Achaogen Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Achaogen Hospital Acquired Pneumonia Drugs Product Portfolio
6.9.5 Achaogen Recent Developments/Updates
6.10 AstraZeneca
6.10.1 AstraZeneca Corporation Information
6.10.2 AstraZeneca Description and Business Overview
6.10.3 AstraZeneca Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 AstraZeneca Hospital Acquired Pneumonia Drugs Product Portfolio
6.10.5 AstraZeneca Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Hospital Acquired Pneumonia Drugs Industry Chain Analysis
7.2 Hospital Acquired Pneumonia Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Hospital Acquired Pneumonia Drugs Production Mode & Process
7.4 Hospital Acquired Pneumonia Drugs Sales and Marketing
7.4.1 Hospital Acquired Pneumonia Drugs Sales Channels
7.4.2 Hospital Acquired Pneumonia Drugs Distributors
7.5 Hospital Acquired Pneumonia Drugs Customers
8 Hospital Acquired Pneumonia Drugs Market Dynamics
8.1 Hospital Acquired Pneumonia Drugs Industry Trends
8.2 Hospital Acquired Pneumonia Drugs Market Drivers
8.3 Hospital Acquired Pneumonia Drugs Market Challenges
8.4 Hospital Acquired Pneumonia Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
